<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04617743</url>
  </required_header>
  <id_info>
    <org_study_id>IMU Urology</org_study_id>
    <nct_id>NCT04617743</nct_id>
  </id_info>
  <brief_title>The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression</brief_title>
  <official_title>The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and Progression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul Medeniyet University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul Medeniyet University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although transurethral resection is the main treatment option for stage Ta and T1 disease,&#xD;
      relapse is frequently detected. Tumor number, tumor size, T stage, presence of in situ&#xD;
      carcinoma and tumor grade are risk factors for recurrence. The relationship between post&#xD;
      voiding residual urine volume and bladder tumor recurrence and progression has not been&#xD;
      clearly established. The investigators aimed to examine the effect of high post voiding&#xD;
      residual urine volume on recurrence and progression based on the hypothesis that tumor cells&#xD;
      circulating in the bladder may increase with excess residual urine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although transurethral resection is the main treatment option for stage Ta and T1 disease,&#xD;
      relapse is frequently detected. Tumor number, tumor size, T stage, presence of in situ&#xD;
      carcinoma and tumor grade are risk factors for recurrence. The relationship between post&#xD;
      voiding residual urine volume and bladder tumor recurrence and progression has not been&#xD;
      clearly established. Participants who underwent transurethral resection for bladder tumor&#xD;
      will be included in the study. The investigators aimed to examine the effect of high post&#xD;
      voiding residual urine volume on recurrence and progression based on the hypothesis that&#xD;
      tumor cells circulating in the bladder may increase with excess residual urine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 26, 2020</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Recurrence</measure>
    <time_frame>1 year</time_frame>
    <description>Non-muscle invasive bladder cancer recurrence rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression</measure>
    <time_frame>1 year</time_frame>
    <description>Non-muscle invasive bladder cancer progression rate</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Bladder Cancer Recurrent</condition>
  <condition>Non-Invasive Bladder Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>High residual volume</arm_group_label>
    <description>Bladder tumor patients with high residual volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low residual volume</arm_group_label>
    <description>Bladder tumor patients with low residual volume</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with transitional cell non-muscle invasive bladder cancer pathology and patients&#xD;
        with follow-up data&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with transitional cell non-muscle invasive bladder cancer (NMIBC) pathology&#xD;
&#xD;
          -  Patients with a diagnosis of Bladder cancer (NMIBC)&#xD;
&#xD;
          -  Patients undergoing transurethral resection for bladder cancer (NMIBC)&#xD;
&#xD;
          -  ≥18 years old patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Non-transitional cell bladder cancers&#xD;
&#xD;
          -  Patients with muscle-invasive bladder cancer pathology&#xD;
&#xD;
          -  &lt;18 years old patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Caglar Cakici, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istanbul Medeniyet University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mehmet Caglar Cakici, M.D.</last_name>
    <phone>+90 5376102438</phone>
    <email>mcaglarcakici@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Health Sciences University, Dıskapi Yildirim Beyazit Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nihat Karakoyunlu, Assoc.Prof.</last_name>
      <phone>+90 5324747134</phone>
      <email>nkarakoyunlu@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istanbul Medeniyet University</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehmet Caglar Cakici, M.D.</last_name>
      <phone>+90 5376102438</phone>
      <email>mcaglarcakici@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health Sciences University, Tepecik Training and Research Hospital</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erdem Kısa, Assoc.Prof</last_name>
      <phone>+90 5052234221</phone>
      <email>drerdemkisa@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <results_reference>
    <citation>Sazuka T, Sakamoto S, Nakamura K, Imamura Y, Yamamoto S, Komiya A, Ichikawa T. Impact of post-void residual urine volume on intravesical recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Int J Urol. 2019 Dec;26(12):1106-1112. doi: 10.1111/iju.14103. Epub 2019 Sep 14.</citation>
    <PMID>31522458</PMID>
  </results_reference>
  <results_reference>
    <citation>Sazuka T, Sakamoto S, Imamura Y, Nakamura K, Yamamoto S, Arai T, Takeuchi N, Komiya A, Teishima J, Ichikawa T. Relationship between post-void residual urine volume, preoperative pyuria and intravesical recurrence after transurethral resection of bladder carcinoma. Int J Urol. 2020 Nov;27(11):1024-1030. doi: 10.1111/iju.14352. Epub 2020 Sep 1.</citation>
    <PMID>32875619</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2020</study_first_posted>
  <last_update_submitted>November 25, 2020</last_update_submitted>
  <last_update_submitted_qc>November 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul Medeniyet University</investigator_affiliation>
    <investigator_full_name>Mehmet Caglar Cakici</investigator_full_name>
    <investigator_title>Department of Urology</investigator_title>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>post voiding residual urine</keyword>
  <keyword>recurrence</keyword>
  <keyword>non-muscle invasive bladder cancer</keyword>
  <keyword>progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

